| Literature DB >> 34093708 |
Shahram Shahraki Zahedani1, Hamed Tahmasebi2, Mojdeh Jahantigh1.
Abstract
BACKGROUND: Biofilm formation and efflux pumps (EPs) correlation play a critical role in the pathogenicity and antibiotic resistance of Pseudomonas aeruginosa. In this study, biofilm formation and EP's collaborative role in clinical isolates of P. aeruginosa infection were investigated.Entities:
Year: 2021 PMID: 34093708 PMCID: PMC8163533 DOI: 10.1155/2021/5557361
Source DB: PubMed Journal: Int J Microbiol
Oligonucleotide sequences used in this study and thermal cycling conditions.
| Gene | Sequence of primers | Thermal cycles | Product size (bp) | Ref |
|---|---|---|---|---|
|
| F: CTCGACCCGATCTACGTC | 95°C/5 min; (95°C/1 min, 56°C/30sec, 72°C/45sec) X30; 72°C/5 min | 503 | [ |
| R: GTCTTCACCTCGACACCC | ||||
|
| ||||
|
| F: TGTCGAAGTTTTTCATTGAG | 95°C/5 min; (95°C/1 min, 58°C/45sec, 72°C/45sec) X35; 72°C/5 min | 280 | [ |
| R: AAGGTCAC GGTGATGGT | ||||
|
| ||||
|
| F: GATCCCCGACTACCAGCGCCCCG | 95°C/5 min; (95°C/1 min, 57°C/1 min, 72°C/45sec) X30; 72°C/5 min | 247 | [ |
| R: ATGCGGTACTGCGCCCGGAAGGC | ||||
|
| ||||
|
| F: ATCTACCGCACAAACGATGAG | 95°C/5 min; (95°C/1 min, 59°C/45sec, 72°C/1 min) X30; 72°C/5 min | 156 | [ |
| R: GCCGAAGCCGATATAATCAAAC | ||||
|
| ||||
|
| F: AAGAATCCGCGCGTTCAATCG | 95°C/7 min; (95°C/1 min, 55°C/1 min, 72°C/50sec) X35; 72°C/10 min | 138 | [ |
| R: GCCCGGCACCGGCATAAT | ||||
|
| ||||
|
| F: CCGAATGCGTATGATTCTCC | 95°C/10 min; (95°C/1 min, 57°C/30sec, 72°C/1 min) X30; 72°C/10 min | 84 | [ |
| R: CGCTTTACTGGCACTTCAGC | ||||
|
| ||||
|
| F: CCGCCATGACCAACTATCTC | 95°C/5 min; (95°C/1 min, 58°C/1 min, 72°C/1 min) X30; 72°C/5 min | 249 | [ |
| R: GCTGGCCGTAGACGAACATC | ||||
The biofilm-forming capacity of P. aeruginosa and percentages of their efflux pump genes related to antibiotics.
| Biofilm | Efflux pump genes | IMI | MER | GEN | CIP | ATM | CPE | CAZ | C | AMK | TMP/SMX | MDR | XDR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RND types | MFS types | SMR types | |||||||||||||||||
|
|
|
|
|
|
|
| |||||||||||||
| Strong ( | 12 | 19 | 17 | 19 | 11 | 8 | 7 | 11 | 9 | 19 | 16 | 7 | 6 | 9 | 1 | 16 | 7 | 14 | 9 |
| Moderate ( | 19 | 7 | 28 | 29 | 3 | 11 | 11 | 6 | 2 | 22 | 28 | 7 | 15 | 0 | 0 | 5 | 12 | 7 | 1 |
| Weak ( | 9 | 4 | 3 | 3 | 8 | 0 | 3 | 2 | 4 | 4 | 9 | 2 | 9 | 1 | 0 | 8 | 0 | 1 | 1 |
| Clinical isolates | |||||||||||||||||||
| Wound ( | 15 | 19 | 18 | 20 | 9 | 4 | 10 | 6 | 5 | 13 | 19 | 6 | 14 | 4 | 1 | 3 | 5 | 11 | 4 |
| Urine ( | 9 | 11 | 14 | 12 | 11 | 14 | 7 | 2 | 1 | 14 | 15 | 1 | 1 | 2 | 0 | 9 | 5 | 5 | 2 |
| Blood ( | 12 | 3 | 24 | 27 | 2 | 1 | 3 | 11 | 9 | 21 | 24 | 10 | 17 | 6 | 0 | 17 | 8 | 6 | 5 |
| Medical devices ( | 8 | 1 | 3 | 4 | 0 | 0 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Gender | |||||||||||||||||||
| Male ( | 19 | 11 | 19 | 13 | 11 | 7 | 6 | 7 | 13 | 17 | 19 | 10 | 8 | 4 | 1 | 17 | 6 | 13 | 5 |
| Female ( | 25 | 22 | 40 | 48 | 11 | 12 | 15 | 12 | 2 | 33 | 42 | 7 | 24 | 8 | 0 | 12 | 13 | 9 | 6 |
| Hospital sections | |||||||||||||||||||
| Maternity unit ( | 6 | 3 | 4 | 6 | 5 | 1 | 3 | 0 | 0 | 5 | 6 | 1 | 2 | 0 | 1 | 2 | 0 | 2 | 0 |
| Pediatrics ( | 3 | 1 | 11 | 11 | 2 | 3 | 1 | 1 | 2 | 3 | 10 | 2 | 4 | 0 | 0 | 2 | 0 | 1 | 0 |
| Internal unit ( | 6 | 1 | 5 | 9 | 3 | 1 | 1 | 1 | 1 | 1 | 7 | 1 | 3 | 1 | 0 | 1 | 2 | 1 | 1 |
| Emergency ( | 10 | 9 | 11 | 13 | 1 | 3 | 6 | 3 | 2 | 11 | 10 | 1 | 7 | 0 | 0 | 7 | 1 | 1 | 1 |
| ICU ( | 7 | 11 | 13 | 9 | 5 | 9 | 2 | 3 | 1 | 15 | 15 | 3 | 5 | 7 | 0 | 6 | 7 | 7 | 3 |
| Burns unit ( | 12 | 8 | 14 | 13 | 6 | 4 | 8 | 11 | 9 | 14 | 13 | 9 | 13 | 4 | 0 | 11 | 9 | 10 | 6 |
| Neurosurgery ( | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMI: imipenem; MER: meropenem; GEN: gentamycin; CIP: ciprofloxacin; ATM: aztreonam; CPE: cefepime; C: colistin; AMK: amikacin; TMP/SMX: trimethoprim/sulfamethoxazole; ICU: Intensive Care Unit.
Figure 1Antibiotic resistance pattern in clinical isolates of P. aeruginosa. IMI: imipenem; MER: meropenem; GEN: gentamycin; CIP: ciprofloxacin; ATM: aztreonam; CPE: cefepime; C: colistin; AMK: amikacin; TMP/SMX: trimethoprim/sulfamethoxazole.
Figure 2The amplification and gel electrophoresis agarose 2% of EP genes in P. aeruginosa. (a) mexA with 503 bp, mexB with 280 bp; well 1: positive control, wells 3 to 9: positive strains with mexB; well 10: positive control, and wells 11 to 18: positive strains with mexA. (b) oprM with 247 bp, oprD with 156 bp; well 2: positive control, wells 3 to 10: positive strains with oprM; well 11: positive control, and wells 12 to 18: positive strains with oprD. (c) tetA with 138 bp, tetR with 84 bp; well 1: positive control, wells 2 to 7: positive strains with tetA; well 7: positive control, and wells 8 to 14: positive strains with tetR. (d) emrE with 249 bp; well 1: positive control and wells 2 to 8: positive strains with emrE. M Ladder 100 bp.
Figure 3Association between efflux pump genes, antibiotic resistance, biofilm formation, and clinical samples in P. aeruginosa isolates. (a) Association between efflux pump genes, antibiotic resistance, and biofilm formation. (b) Association between efflux pump genes and clinical samples. Each dataset was analyzed using Student's t-test and the two-way ANOVA and was presented as Mean + SEM. p value <0.05; p value <0.01; p value <0.001; and p value <0.0001. ns: nonsense.
Correlation between efflux pumps, biofilm formation, separated clinical isolates, and antibiotic resistance in P. aeruginosa.
| Biofilm | Efflux pump families | ||||||
|---|---|---|---|---|---|---|---|
| RND types | MFS types | SMR types | |||||
|
|
|
|
|
|
|
| |
| Strong |
|
|
|
|
|
|
|
| Moderate |
|
|
|
|
|
|
|
| Weak |
|
|
|
|
|
|
|
|
| |||||||
| Clinical isolates | |||||||
| Wound |
|
|
|
|
|
|
|
| Urine |
|
|
|
|
|
|
|
| Blood |
|
|
|
|
|
|
|
| Medical devices |
|
|
|
|
|
|
|
|
| |||||||
| Gender | |||||||
| Male |
|
|
|
|
|
|
|
| Female | 0.085 | 0.020 | 0.009 | 0.005 | 0.066 | 0.043 | 0.051 |
| Hospital sections | |||||||
| Maternity unit |
|
|
|
|
|
|
|
| Pediatrics |
|
|
|
|
|
|
|
| Internal unit |
|
|
|
|
|
|
|
| Emergency | 0.025 | 0.015 | 0.084 | 0.001 | 0.075 | 0.033 | 0.019 |
| ICU |
|
|
|
|
|
|
|
| Burns unit |
|
|
|
|
|
|
|
| Neurosurgery |
|
|
|
|
|
|
|